Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q2 2018 · 10-Q
Revenue$11.08M$11.08M−9.7% vs Q2 2017 Net Income-$1.26M-$1.26MN/M vs Q2 2017 EPS Diluted-$0.07-$0.07N/M vs Q2 2017 Gross Profit$2,388,999+2.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
Operating Cash Flowderived$180,210N/M Margins · derivedGross margin21.6%+2.6 pt vs Q2 2017
Operating margin-8.5%+20.1 pt vs Q2 2017
Net margin-11.4%+15.4 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 14, 2018 · 45 d after period end